Vitamin K and Cognition in Coronary Heart Disease (NutriCog) (Nutricog)
Vitamin K Supplementation to Improve Cognition of Patients With Coronary Heart Disease: a Randomized Controlled Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Guylaine Ferland, PhD
- Phone Number: 3374 +1 (514) 376-3330
- Email: guylaine.ferland@umontreal.ca
Study Contact Backup
- Name: Bouchra Ouliass, B.Sc.
- Phone Number: 4043 +1 (514) 376-3330
- Email: Bouchra.Ouliass@icm-mhi.org
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Montreal Heart Institute
-
Contact:
- Guylaine Ferland, PhD
- Phone Number: 3374 +1 (514) 376-3330
- Email: guylaine.ferland@umontreal.ca
-
Principal Investigator:
- Guylaine Ferland, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women
- Age 60 years and older
- Medically documented stable Coronary Heart Disease (CHD)
- Daily dietary intakes of phylloquinone <150 mcg
- Non-consumption of vitamin K supplements (i.e. K1 or K2, singly or in combination with other nutrients), or other cognitive aids
- Good French or English understanding
- Physical exercise not exceeding 2.5 hours/week of moderate to vigorous aerobic activity
- Capacity and willingness to sign informed consent
Exclusion Criteria:
- Recent acute coronary syndrome (<3 months) or recent coronary revascularization (bypass surgery or percutaneous coronary intervention, <3 months)
- Known left ventricular dysfunction (LVEF < 40%) or chronic heart failure
- Recent modification of medication (<2 weeks)
- Warfarin (Coumadin) use
- Cognitive impairment (based on telephone version of the Mini-Mental State Examination test, score <19/23)
- Diagnosis of depression or uncontrolled anxiety
- Malabsorption disorder (advanced liver disease, Crohn's disease)
- Patient with auditory or vision impairments not properly corrected by glasses or hearing aids
- Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dietary Supplement: Vitamin K
Participants receive 0.5 mg/day phylloquinone orally for 12 weeks
|
Participants receive 0.5 mg/day phylloquinone orally for 12 weeks
|
|
Placebo Comparator: Dietary Supplement: Placebo
Participants receive daily placebo for 12 weeks
|
Participants receive daily placebo for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in general cognitive functioning
Time Frame: Baseline and post-intervention at 12 weeks
|
Montreal Cognitive Assessment (0-30 score, with a higher score indicating a better cognitive functioning)
|
Baseline and post-intervention at 12 weeks
|
|
Change in processing speed
Time Frame: Baseline and post-intervention at 12 weeks
|
Processing speed is assessed using the Coding subtest from the Wechsler Adult Intelligence Scale (WAIS)IV.
The participant is asked to reproduce, as rapidly as possible, a series of symbols associated with digits in a 2-min time period
|
Baseline and post-intervention at 12 weeks
|
|
Change in executive functions
Time Frame: Baseline and post-intervention at 12 weeks
|
Executive function is assessed using
As these tests use different scales, z-scores will be calculated for the different tests and a composite z-score will be generated for the domain |
Baseline and post-intervention at 12 weeks
|
|
Change in episodic memory
Time Frame: Baseline and post-intervention at 12 weeks
|
Episodic memory is assessed using:
As these tests use different scales, z-scores will be calculated for the different tests and a composite z-score will be generated for the domain |
Baseline and post-intervention at 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cerebral autoregulation - middle cerebral arteries
Time Frame: Baseline and post-intervention at 12 weeks
|
Variations of cerebral blood flow velocity at the level of the middle cerebral artery will be measured in response to hypercapnic breathing using transcranial Doppler (TCD)
|
Baseline and post-intervention at 12 weeks
|
|
Change in cerebral pulsatility - middle cerebral arteries
Time Frame: Baseline and post-intervention at 12 weeks
|
Pulsatility will be measured as the normalized difference of relative blood flow velocities between systole and diastole, using TCD in the middle cerebral arteries
|
Baseline and post-intervention at 12 weeks
|
|
Change in peripheral endothelial function
Time Frame: Baseline and post-intervention at 12 weeks
|
Brachial artery flow-mediated dilation (FMD) will be quantified noninvasively by measuring blood velocity in the brachial artery and its diameter before and after 5 minutes of forearm hypoxia, using a high-resolution ultrasound device
|
Baseline and post-intervention at 12 weeks
|
|
Central arterial stiffness
Time Frame: Baseline and post-intervention at 12 weeks
|
Central arterial stiffness will be assessed by measuring the carotid-femoral pulse-wave velocity (cfPWV), using a non-invasive surface tonometer
|
Baseline and post-intervention at 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guylaine Ferland, PhD, Université de Montréal
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antifibrinolytic Agents
- Fibrin Modulating Agents
- Hemostatics
- Coagulants
- Micronutrients
- Vitamins
- Vitamin K
Other Study ID Numbers
Other Study ID Numbers
- 2022-3025
- (FRN) 183781_1 (Other Grant/Funding Number: Canadian Institutes of Health Research (CIHR))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.